Pharmacovigilance – News and Features

The patented Mitox™ technology covers the measurement of mitochondrial DNA and RNA as a biomarker in the assessment of efficacy and unwanted adverse events of treatment.

CYP2D6 affects the metabolism of a large number of compounds, including several commonly prescribed cardiovascular, anti-depressant and analgesic drugs.

A brand new laboratory, which includes a GMP facility and pharmaceutical and chemical laboratories, has been set up.

Protein MBD2 mediates silencing of the fetal gamma-globin gene through DNA methylation.

The Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients.

Third Wave will accelerate and expand the development of high-value clinical products for the Japanese molecular diagnostic market.

Four scientists from Children's Memorial Research Center in Chicago have launched the contract research organization based in Evanston, Illinois.

Clinical Trials for Patented Nanotechnology-Based Therapeutic Set to Begin

BG Medicine has announced a collaborative preclinical research study into the biochemical origins of muscle toxicity and associated biomarkers with Mitsubishi Pharma Corp.

BG Medicine will apply their integrated systems approach to describe the molecular effects of selected lipid lowering agents on skeletal muscle.